The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (2024)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (1) https://doi.org/10.1038/s41523-021-00241-9 · The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (2)

Видання: npj Breast Cancer, 2021, №1

Видавець: Springer Science and Business Media LLC

Автори:

  1. Natansh D. Modi
  2. Jin Quan Eugene Tan
  3. Andrew Rowland
  4. Bogda Koczwara
  5. Ahmad Y. Abuhelwa
  6. Ganessan Kichenadasse
  7. Ross A. McKinnon
  8. Michael D. Wiese
  9. Michael J. Sorich
  10. Ashley M. Hopkins

Анотація

AbstractWhile many studies have evaluated the relationship between BMI and breast cancer outcomes, it is unclear whether this relationship is consistent between early breast cancer (BC) and advanced BC. The study included 5099 patients with HER2 positive early BC (EBC) and 3496 with HER2 positive advanced BC (ABC). In the EBC cohort, higher BMI was associated with worse overall survival (OS) (HR [95% CI]: overweight = 1.30 [1.13–1.51]; obese = 1.37 [1.14–1.64], P = < 0.001), and worse disease-free survival (overweight = 1.10 [0.98–1.24]; obese = 1.20 [1.04–1.39], P = 0.061). In contrast, for the ABC cohort, higher BMI was significantly associated with improved OS (overweight = 0.85 [0.76–0.96]; obese = 0.82 [0.72–0.95], P = 0.014), and progression-free survival (overweight = 0.91 [0.83–1.01]; obese = 0.87 [0.77–0.98], P = 0.034). In this large high-quality dataset, higher BMI was independently associated with worse survival in EBC, paradoxically in ABC higher BMI was independently associated with improved survival.

Джерела фінансування

  1. Cancer Council South Australia
  2. National Breast Cancer Foundation

Список літератури

  1. Ellingjord-Dale, M. et al. Number of risky lifestyle behaviors and breast cancer risk. JNCI Cancer Spectr. 2, 8 (2018).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (3) https://doi.org/10.1093/jncics/pky030
  2. Liu, K. et al. Association between body mass index and breast cancer risk: evidence based on a dose-response meta-analysis. Cancer Manag. Res. 10, 143–151 (2018).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (4) https://doi.org/10.2147/CMAR.S144619
  3. Key, T. J. et al. Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. Steroids 99, 49–55 (2015).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (5) https://doi.org/10.1016/j.steroids.2014.09.001
  4. Picon‐Ruiz, M., Morata‐Tarifa, C., Valle‐Goffin, J., Friedman, E. R. & Slingerland, J. M. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J. Clin. 67, 378–397 (2017).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (6) https://doi.org/10.3322/caac.21405
  5. Gennari, A. et al. Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. Breast Cancer Res. Treat. 159, 79–86 (2016).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (7) https://doi.org/10.1007/s10549-016-3923-8
  6. Cecchini, R. S. et al. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiol. Biomarkers Prev. 25, 51–59 (2016).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (8) https://doi.org/10.1158/1055-9965.EPI-15-0334-T
  7. Chan, D. S. M. & Norat, T. Obesity and breast cancer: not only a risk factor of the disease. Curr. Treat. Options Oncol. 16, 22 (2015).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (9) https://doi.org/10.1007/s11864-015-0341-9
  8. Trestini, I., Carbognin, L., Bonaiuto, C., Tortora, G. & Bria, E. The obesity paradox in cancer: clinical insights and perspectives. Eat. Weight Disord. 23, 185–193 (2018).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (10) https://doi.org/10.1007/s40519-018-0489-y
  9. Crozier, J. A. et al. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer 119, 2447–2454 (2013).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (11) https://doi.org/10.1002/cncr.28051
  10. Yerushalmi, R. et al. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann. Oncol. 28, 1560–1568 (2017).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (12) https://doi.org/10.1093/annonc/mdx152
  11. Chan, D. S. M. et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann. Oncol. 25, 1901–1914 (2014).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (13) https://doi.org/10.1093/annonc/mdu042
  12. Ewertz, M. et al. Effect of obesity on prognosis after early-stage breast cancer. J. Clin. Oncol. 29, 25–31 (2011).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (14) https://doi.org/10.1200/JCO.2010.29.7614
  13. Lee, K., Kruper, L., Dielie-Conwright, C. & Mortimer, J. The impact of obesity on breast cancer diagnosis and treatment. Curr. Oncol. Rep. 21 https://doi.org/10.1007/s11912-019-0787-1 (2019).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (15) https://doi.org/10.1007/s11912-019-0787-1
  14. Yazici, O. et al. The effect of obesity on recurrence pattern in early breast cancer patients. J. Boun 20, 954–962 (2015).
  15. Garcia-Estevez, L. & Moreno-Bueno, G. Updating the role of obesity and cholesterol in breast cancer. Breast Cancer Res. 21, https://doi.org/10.1186/s13058-019-1124-1 (2019).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (16) https://doi.org/10.1186/s13058-019-1124-1
  16. Bergom, C. et al. Association of locoregional control with high body mass index in women undergoing breast conservation therapy for early-stage breast cancer. Int J. Radiat. Oncol. Biol. Phys. 96, 65–71 (2016).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (17) https://doi.org/10.1016/j.ijrobp.2016.04.020
  17. Pajares, B. et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res. 15, R105–R105 (2013).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (18) https://doi.org/10.1186/bcr3572
  18. Sparano, J. A. et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118, 5937–5946 (2012).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (19) https://doi.org/10.1002/cncr.27527
  19. Guo, Q. et al. Body mass index and breast cancer survival: a Mendelian randomization analysis. Int. J. Epidemiol. 46, 1814–1822 (2017).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (20) https://doi.org/10.1093/ije/dyx131
  20. Sun, L., Zhu, Y., Qian, Q. & Tang, L. Body mass index and prognosis of breast cancer. Medicine 97, e11220 (2018).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (21) https://doi.org/10.1097/MD.0000000000011220
  21. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F. & Zwahlenm, M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–578 (2008).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (22) https://doi.org/10.1016/S0140-6736(08)60269-X
  22. Klil-Drori, A. J., Azoulay, L. & Pollak, M. N. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat. Rev. Clin. Oncol. 14, 85–99 (2017).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (23) https://doi.org/10.1038/nrclinonc.2016.120
  23. Lennon, H., Sperrin, M., Badrick, E. & Renehan, A. G. The obesity paradox in cancer: a review. Curr. Oncol. Rep. 18, 56 (2016).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (24) https://doi.org/10.1007/s11912-016-0539-4
  24. Basen-Engquist, K. & Chang, M. Obesity and cancer risk: recent review and evidence. Curr. Oncol. Rep. 13, 71–76 (2011).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (25) https://doi.org/10.1007/s11912-010-0139-7
  25. Lauby-Secretan, B. et al. Body fatness and cancer—viewpoint of the IARC Working Group. N. Engl. J. Med. 375, 794–798 (2016).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (26) https://doi.org/10.1056/NEJMsr1606602
  26. Krasniqi, E. et al. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. J. Cell. Physiol. 1–11, https://doi.org/10.1002/jcp.29445 (2020).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (27) https://doi.org/10.1002/jcp.29445
  27. Dawood, S. et al. Prognostic value of body mass index in locally advanced breast cancer. J. Clin. Cancer Res. 14, 1718–1725, https://doi.org/10.1158/1078-0432.CCR-07-1479 (2008).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (28) https://doi.org/10.1158/1078-0432.CCR-07-1479
  28. von Drygalski, A. et al. Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support. Int. J. Breast Cancer 2011, 523276 (2011).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (29) https://doi.org/10.4061/2011/523276
  29. Barba, M. et al. Body mass index and treatment outcomes in metastatic breast cancer patients treated with eribulin. J. Cell Physiol. 231, 986–991 (2016).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (30) https://doi.org/10.1002/jcp.25213
  30. Pizzuti, L. et al. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Cancer Biol. Ther. 19, 328–334 (2018).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (31) https://doi.org/10.1080/15384047.2017.1416938
  31. Martel, S. et al. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. Breast 37, 142–147 (2018).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (32) https://doi.org/10.1016/j.breast.2017.11.004
  32. Alarfi, H. et al. The impact of baseline body mass index on clinical outcomes in metastatic breast cancer: a prospective study. BMC Res. Notes 10, 550 (2017).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (33) https://doi.org/10.1186/s13104-017-2876-2
  33. Parolin, V. et al Impact of BMI on clinical outcome of HER2-positive breast cancer. J. Clin. Oncol. 28, abstract 1130, https://doi.org/10.1200/jco.2010.28.15_suppl.1130 (2010).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (34) https://doi.org/10.1200/jco.2010.28.15_suppl.1130
  34. Gennari, A. et al. Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy. Cancer Epidemiol. Biomarkers Prev. 22, 1862–1867 (2013).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (35) https://doi.org/10.1158/1055-9965.EPI-13-0595
  35. Franzoi, M. A. et al. Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy. J Natl. Cancer Inst. https://doi.org/10.1093/jnci/djaa116 (2020).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (36) https://doi.org/10.1093/jnci/djaa116
  36. Simkens, L. H. et al. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur. J. Cancer 47, 2560–2567 (2011).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (37) https://doi.org/10.1016/j.ejca.2011.06.038
  37. McQuade, J. L. et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 19, 310–322 (2018).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (38) https://doi.org/10.1016/S1470-2045(18)30078-0
  38. Schneider, G., Kirschner, M. A., Berkowitz, R. & Ertel, N. H. Increased estrogen production in obese men. J. Clin. Endocrinol. Metab. 48, 633–638 (1979).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (39) https://doi.org/10.1210/jcem-48-4-633
  39. Dhanapal, R., Saraswathi, T. & Govind, R. Cancer cachexia. J. Oral. Maxillofac. Pathol. 15, 257–260 (2011).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (40) https://doi.org/10.4103/0973-029X.86670
  40. Meng, L. et al. Effect of early nutrition intervention on advanced nasopharyngeal carcinoma patients receiving chemoradiotherapy. J. Cancer 10, 3650–3656 (2019).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (41) https://doi.org/10.7150/jca.33475
  41. Deluche, E. et al. Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer 26, 861–868 (2018).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (42) https://doi.org/10.1007/s00520-017-3902-6
  42. Maskarinec, G. et al. Factors affecting survival among women with breast cancer in Hawaii. J. Womens Health 20, 231–237 (2011).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (43) https://doi.org/10.1089/jwh.2010.2114
  43. Kamineni, A. et al. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes Control 24, 305–312 (2013).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (44) https://doi.org/10.1007/s10552-012-0115-7
  44. Faraoni, D. & Schaefer, S. T. Randomized controlled trials vs. observational studies: why not just live together? BMC Anesthesiol. 16, 102–102 (2016).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (45) https://doi.org/10.1186/s12871-016-0265-3
  45. Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D. & Ogden, C. L. Trends in obesity among adults in the United States, 2005 to 2014. Jama 315, 2284–2291 (2016).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (46) https://doi.org/10.1001/jama.2016.6458
  46. Blair, C. K. et al. Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. npj Breast Cancer 5, 33 (2019).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (47) https://doi.org/10.1038/s41523-019-0128-4
  47. VanderWeele, T. J. On the relative nature of overadjustment and unnecessary adjustment. Epidemiology. 20, 496–499 (2009).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (48) https://doi.org/10.1097/EDE.0b013e3181a82f12
  48. Schisterman, E. F., Cole, S. R. & Platt, R. W. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20, 488–495 (2009).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (49) https://doi.org/10.1097/EDE.0b013e3181a819a1
  49. Bradley, C., Given, C. & Roberts, C. Race, socioeconomic status, and breast cancer treatment and survival. J. Natl. Cancer Inst. 94, 490–496 (2002).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (50) https://doi.org/10.1093/jnci/94.7.490
  50. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (51) https://doi.org/10.1056/NEJMoa052306
  51. Cameron, D. et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet 389, 1195–1205 (2017).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (52) https://doi.org/10.1016/S0140-6736(16)32616-2
  52. Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724–734 (2015).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (53) https://doi.org/10.1056/NEJMoa1413513
  53. Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14, 461–471 (2013).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (54) https://doi.org/10.1016/S1470-2045(13)70130-X
  54. Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109–119 (2012).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (55) https://doi.org/10.1056/NEJMoa1113216
  55. Perez, E. A. et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J. Clin. Oncol. 35, 141–148 (2016).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (56) https://doi.org/10.1200/JCO.2016.67.4887
  56. Perez, E. A. et al. Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: final overall survival (OS) and safety from MARIANNE. J. Clin. Oncol. 35, 1003–1003 (2017).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (57) https://doi.org/10.1200/JCO.2017.35.15_suppl.1003
  57. Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (58) https://doi.org/10.1056/NEJMoa1209124
  58. Diéras, V. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 732–742 (2017).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (59) https://doi.org/10.1016/S1470-2045(17)30312-1
  59. Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 18, 743–754 (2017).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (60) https://doi.org/10.1016/S1470-2045(17)30313-3
  60. Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 689–699 (2014).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (61) https://doi.org/10.1016/S1470-2045(14)70178-0
  61. Nuttall, F. Q. Body mass index: obesity, bmi, and health: a critical review. Nutr. Today 50, 117–128 (2015).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (62) https://doi.org/10.1097/NT.0000000000000092
  62. Modi, N. D. et al. Metadata record for the manuscript: the obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. figshare, https://doi.org/10.6084/m9.figshare.14046287 (2021).
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (63) https://doi.org/10.6084/m9.figshare.14046287

Публікації, які цитують цю публікацію

De novo Creation and Assessment of a Prognostic Fat-Age-Inflammation Index “FAIN” in Patients With Cancer: A Multicenter Cohort Study

Liangyu Yin, Chunhua Song, Jiuwei Cui, Xin Lin, Na Li, Yang Fan, Ling Zhang, Jie Liu, Feifei Chong, Chang Wang, Tingting Liang, Xiangliang Liu, Li Deng, Mei Yang, Jiami Yu, Xiaojie Wang, Xing Liu, Shoumei Yang, Zheng Zuo, Kaitao Yuan, Miao Yu, Minghua Cong, Zengning Li, Min Weng, Qinghua Yao, Pingping Jia, Suyi Li, Zengqing Guo, Wei Li, Hanping Shi, Hongxia Xu

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (64) https://doi.org/10.3389/fnut.2022.860285 · The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (65)

2022, Frontiers in Nutrition

Scopus

WoS

Цитувань Crossref:0

Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy

Simona Rabinovici-Cohen, Xosé M. Fernández, Beatriz Grandal Rejo, Efrat Hexter, Oliver Hijano Cubelos, Juha Pajula, Harri Pölönen, Fabien Reyal, Michal Rosen-Zvi

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (66) https://doi.org/10.3390/cancers14163848 · The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (67)

2022, Cancers, №16, с.3848

Scopus

WoS

The obesity-breast cancer link: a multidisciplinary perspective

Emily N. Devericks, Meredith S. Carson, Lauren E. McCullough, Michael F. Coleman, Stephen D. Hursting

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (68) https://doi.org/10.1007/s10555-022-10043-5

2022, Cancer and Metastasis Reviews, №3, с.607-625

Scopus

WoS

Цитувань Crossref:21

Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?

Tania Rossi, Erika Bandini, William Balzi, Francesco Fabbri, Ilaria Massa, Roberta Maltoni

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (69) https://doi.org/10.3389/fmed.2021.725346 · The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (70)

2021, Frontiers in Medicine

Scopus

WoS

Цитувань Crossref:0

Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study

Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Hiroki Matsui, Masahiko Tanabe, Yasuyuki Seto, Hideo Yasunaga

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (71) https://doi.org/10.1007/s10549-022-06638-9 · The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (72)

2022, Breast Cancer Research and Treatment, №2, с.315-325

Scopus

WoS

Цитувань Crossref:0

Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms

Xiaoyang Lan, Nicola Fazio, Omar Abdel-Rahman

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (73) https://doi.org/10.3390/metabo12111150 · The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (74)

2022, Metabolites, №11, с.1150

Scopus

WoS

Цитувань Crossref:1

Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center

Jeffrey Aldrich, Princess Ekpo, Manali Rupji, Jeffrey M. Switchenko, Mylin A. Torres, Kevin Kalinsky, Manali A. Bhave

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (75) https://doi.org/10.1016/j.clbc.2022.10.005

2023, Clinical Breast Cancer, №1, с.38-44

Scopus

WoS

Цитувань Crossref:0

Association between high body mass index and prognosis of patients with early-stage breast cancer: A systematic review and meta-analysis

Zhoujuan Li, Guoshuang Shen, Mingqiang Shi, Yonghui Zheng, Yumei Guan, Yuanfang Xin, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (76) https://doi.org/10.1016/j.cpt.2023.03.002

2023, Cancer Pathogenesis and Therapy, №3, с.205-215

Scopus

Цитувань Crossref:2

Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer

Rikki A. Cannioto, Kristopher M. Attwood, Evan W. Davis, Lucas A. Mendicino, Alan Hutson, Gary R. Zirpoli, Li Tang, Nisha M. Nair, William Barlow, Dawn L. Hershman, Joseph M. Unger, Halle C. F. Moore, Claudine Isaacs, Timothy J. Hobday, Gabriel N. Hortobagyi, Julie R. Gralow, Kathy S. Albain, G. Thomas Budd, Christine B. Ambrosone

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (77) https://doi.org/10.1001/jamanetworkopen.2023.11673 · The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (78)

2023, JAMA Network Open, №5, с.e2311673

Scopus

WoS

Цитувань Crossref:0

The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry

Senna W.M. Lammers, Hannah Thurisch, Ingeborg J.H. Vriens, Marissa Meegdes, Sanne M.E. Engelen, Frans L.G. Erdkamp, M. Wouter Dercksen, Birgit E.P.J. Vriens, Kirsten N.A. Aaldering, Manon J.A.E. Pepels, Linda M.H. van de Winkel, Natascha A.J.B. Peters, Jolien Tol, Joan B. Heijns, Agnes J. van de Wouw, Nathalie J.A. Teeuwen, Sandra M.E. Geurts, Vivianne C.G. Tjan-Heijnen

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (79) https://doi.org/10.21203/rs.3.rs-3156006/v1

2023

Цитувань Crossref:0

Знайти всі цитування публікації

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data (2024)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Greg Kuvalis

Last Updated:

Views: 6332

Rating: 4.4 / 5 (55 voted)

Reviews: 94% of readers found this page helpful

Author information

Name: Greg Kuvalis

Birthday: 1996-12-20

Address: 53157 Trantow Inlet, Townemouth, FL 92564-0267

Phone: +68218650356656

Job: IT Representative

Hobby: Knitting, Amateur radio, Skiing, Running, Mountain biking, Slacklining, Electronics

Introduction: My name is Greg Kuvalis, I am a witty, spotless, beautiful, charming, delightful, thankful, beautiful person who loves writing and wants to share my knowledge and understanding with you.